Dyne Therapeutics (DYN) Projected to Post Quarterly Earnings on Thursday

Dyne Therapeutics (NASDAQ:DYN) is expected to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Dyne Therapeutics to post earnings of ($0.74) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dyne Therapeutics Stock Up 7.8%

Shares of NASDAQ:DYN opened at $18.84 on Thursday. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -5.32 and a beta of 1.08. The firm’s 50-day simple moving average is $18.01 and its 200-day simple moving average is $18.58. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15. Dyne Therapeutics has a fifty-two week low of $8.06 and a fifty-two week high of $25.00.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 83,219 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the completion of the sale, the director directly owned 7,962 shares in the company, valued at $144,749.16. The trade was a 91.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,552,911 shares of company stock worth $29,694,469 in the last ninety days. 14.14% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DYN. Aster Capital Management DIFC Ltd bought a new position in Dyne Therapeutics during the 4th quarter valued at $84,000. Steward Partners Investment Advisory LLC grew its position in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. Verition Fund Management LLC bought a new position in Dyne Therapeutics in the 4th quarter valued at about $204,000. Tower Research Capital LLC TRC grew its position in Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at about $147,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.